TITLE PAGE

The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice:

A Pharmacokinetic and Pharmacodynamic Study

Erin C. Berthold¹, Shyam H. Kamble^{1,2}, Kanumuri S. Raju^{1,2}, Michelle A. Kuntz¹, Alexandria S. Senetra¹, Marco Mottinelli³, Francisco León^{3,#}, Luis F. Restrepo⁴, Avi Patel⁴, Nicholas P. Ho⁴, Takato Hiranita⁴, Abhisheak Sharma^{1,2*}, Lance R. McMahon⁴, Christopher R. McCurdy^{1,2,3*}

¹Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA

²Translational Drug Development Core, Clinical and Translational Science Institute, University of Florida, Gainesville, FL, USA

³Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA

⁴Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA

Keywords: Antinociception, 7-Hydroxymitragynine, *Mitragyna speciosa* (kratom), mitragynine, pharmacokinetics, tissue distribution

Downloaded from dmd.aspetjournals.org at ASPET Journals on April 19, 2024

Running Title Page

7-hydroxymitragynine alone cannot explain mitragynine analgesia

Corresponding Authors:

Dr. Christopher R. McCurdy

University of Florida Clinical and Translational Sciences Institute, Translational Drug Development Core,

Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.

Email: cmccurdy@cop.ufl.edu

Phone: +1 352 294 8691

Dr. Abhisheak Sharma

University of Florida Clinical and Translational Sciences Institute, Translational Drug Development Core,

Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA.

Email: asharma1@cop.ufl.edu

Phone: +1 352 294 8690

Berthold et al., 7-hydroxymitragynine alone cannot explain mitragynine analgesia

Manuscript statistics:

Number of text pages: 17

Number of tables: 3

Number of figures: 8

Number of supplementary tables: 7

Number of supplementary figures: 3

Number of references: 41

Number of characters in the Running Title: 58

Number of words in the Abstract: 238

Number of words in the Significance Statement: 64

Number of words in the Introduction: 767 including all references

Number of words in the Discussion: 1586 including all references

Non-standard abbreviations: 7-hydroxymitragynine (7HMG), Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), analysis of variance (ANOVA), blood brain barrier (BBB), confidence interval (CI), correlation coefficient (r^2), effect concentration to reach 50 percent maximum effect (EC₅₀), effective dose to achieve 50 percent maximum possible effect (ED₅₀), Food and Drug Administration (FDA), Food and Drug Administration Adverse Event Reporting System (FAERS), guanosine 5'-O-[γ-thio]triphosphate (GTPyS), half-life (t_{1/2}), high quality control (HQC), hydrochloride (HCl), Institutional Animal Care and Use Committee (IACUC), intraperitoneal (i.p.), internal standard (IS), liquid chromatography high-resolution quadrupole time of flight mass spectrometry (LC-Q-TOF-MS), lower limit of quantification (LLOQ), low quality control (LQC), mitragynine (MTG), µ-opioid receptor (MOR), maximum concentration (C_{max}), mouse liver microsomes (MLM), maximum possible effect (MPE), medium quality control (MQC), National Institutes of Health (NIH), nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt (NADPH), nuclear magnetic resonance spectroscopy (NMR), percent bias (%Bias), per os (p.o.), proton nuclear magnetic resonance spectroscopy (¹H NMR), pharmacokinetic-pharmacodynamic (PK/PD), carbon nuclear magnetic resonance spectroscopy (13C NMR), quality control (QC), rate constant to effect compartment (ke0), relative standard deviation (RSD), standard deviation (SD), standard error of mean (SEM), ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS), ultra-high-performance liquid chromatographyphotodiode array detection (UHPLC-PDA), volume of distribution (V/F)

ABSTRACT

Kratom (Mitragyna speciosa), a Southeast Asian tree, has been used for centuries in pain relief and mitigation of opium withdrawal symptoms. Mitragynine, the major kratom alkaloid, is being investigated for its potential to provide analgesia without the deleterious effects associated with typical opioids. Concerns have been raised regarding the active metabolite of mitragynine, 7-hydroxymitragynine, which has higher affinity and efficacy at μ-opioid receptors than mitragynine. Here we investigated the hotplate antinociception, pharmacokinetics, and tissue distribution of mitragynine and 7-hydroxymitragynine at equianalgesic oral doses in male and female C57BL/6 mice to determine the extent to which 7-hydroxymitragynine metabolized from mitragynine accounts for the antinociceptive effects of mitragynine and investigate any sex differences. The mechanism of action was examined by performing studies with the opioid receptor antagonist naltrexone. A population pharmacokinetic/pharmacodynamic model was developed to predict the behavioral effects after administration of various doses of mitragynine and 7-hydroxymitragynine. When administered alone, 7-hydroxymitragynine was 2.8-fold more potent than mitragynine to produce antinociception. At equivalent effective doses of mitragynine and 7-hydroxymitragynine, there was a marked difference in the maximum brain concentration of 7hydroxymitragynine achieved, i.e., 11-fold lower as a metabolite of mitragynine. The brain concentration of 7hydroxymitragynine observed 4 hr post administration, producing an analgesic effect < 10%, was still 1.5-fold higher than the maximum concentration of 7-hydroxymitragynine as a metabolite of mitragynine. These results provide strong evidence that 7-hydroxymitragynine has a negligible role in the antinociceptive effects of mitragynine in mice.

Significance Statement.

Mitragynine is being investigated for its potential to aid in pain relief, opioid withdrawal syndrome, and opioid use disorder. The active metabolite of mitragynine, 7-hydroxymitragynine, has been shown to have abuse potential and has been implicated in the opioid-like analgesic effect after mitragynine administration. The results of this study suggest a lack of involvement of 7-hydroxymitragyine in the antinociceptive effects of mitragynine in mice.

INTRODUCTION

Mitragyna speciosa (Korth.) Havil., known in the United States as kratom, is a tree native to Southeast Asia (Sharma and McCurdy, 2021). Traditional use of kratom includes chewing the leaves to sustain energy while working in the hot and humid environment where it grows or brewing the leaves into a tea or decoction for analgesia. It has also been used as a substitution for opium and for the mitigation of opioid withdrawal symptoms (Veltri and Grundmann, 2019). In the Western world, kratom products are primarily used for pain, withdrawal from opioids, anxiety, and depression (Veltri and Grundmann, 2019). The most abundant kratom alkaloid in dried kratom leaves is mitragynine (MTG, Figure 1 left) (Sharma et al., 2019). Although MTG has been reported to account for up to 66% of the total alkaloid content, more recent analyses demonstrate that MTG accounts for 0.7%-38.7% of total alkaloidal content in commercial products and traditional preparations. A metabolite of MTG, 7-hydroxymitragynine (7HMG, Figure 1 right), is also found as <0.01% in fresh samples and ~2% in commercial products (Lydecker et al., 2016; Hemby et al., 2019; Singh et al., 2020; Chear et al., 2021). As a metabolite of MTG, 7HMG formation is primarily catalyzed by cytochrome P450 3A4 enzyme in humans (Kamble et al., 2019).

Kratom alkaloids are active at a variety of receptor types including opioidergic, adrenergic, and serotonergic (Ellis et al., 2020; Obeng et al., 2020; Obeng et al., 2021). Among the receptors, *in vitro* activities of MTG and 7HMG differ at μ-opioid receptors (MOR). 7HMG is a high affinity, partial agonist whereas MTG is a low affinity, partial agonist with K_i values of 37 and 230 nM, respectively (Varadi et al., 2016). MTG differs from other standard MOR agonists as it does not activate the β-arrestin-2 signaling pathway, which has been hypothesized to be the cause of many of the adverse effects of MOR agonists, including respiratory depression and constipation (Eastlack et al., 2020). Study results have also indicated that MTG may produce small but significant analgesia through non-opioid mediated pathways (Matsumoto et al., 1996; Hiranita et al., 2019; Obeng et al., 2020).

Kratom has shown potential as a treatment for opioid dependence, but has also produced adverse events, leading to scrutiny by public health and regulatory officials. In rats self-administering morphine, heroin, or

methamphetamine, MTG was not self-administered above vehicle levels (Yue et al., 2018; Hemby et al., 2019). Additionally, pretreatment with MTG dose dependently decreased the rate of self-administration responding maintained by heroin but not methamphetamine (Yue et al., 2018). These results indicate MTG has limited abuse potential while also functionally antagonizing the reinforcing effects of opioids. Conversely, 7HMG substituted for morphine in assays of self-administration as well as being self-administered in naïve rats (Hemby et al., 2019). These results reveal that 7HMG has a high abuse potential (Hemby et al., 2019). Adverse effects in multiple organ systems have been reported from case studies of kratom users including acute liver failure, acute kidney injury, cardiotoxicity, acute respiratory distress syndrome, acute brain injury, seizures, coma, and even death (Eastlack et al., 2020). As of December 31, 2020, the Food and Drug Administration's (FDA) adverse events reporting system (FAERS) public dashboard included 567 serious cases, and of those, 378 deaths associated with the use of kratom taken alone or concomitantly with other substances (FDA, 2021).

Due to the controversy surrounding the use of kratom products and the abuse potential of 7HMG, it is essential to compare the pharmacokinetic profile of 7HMG alone and converted from MTG to understand the respective contributions of each to the reported effects of MTG. The pharmacokinetic profile of active metabolites is essential for the drug development process, especially if the metabolites are suspected to be more potent and/or pose risks. Here we are investigating the systemic pharmacokinetics and tissue distribution of MTG and 7HMG after an equianalgesic oral dose of either MTG or 7HMG in male and female mice. To identify their equianalgesic doses, the time-effect functions of MTG and 7HMG were assessed using a hotplate assay. The opioid receptor antagonist naltrexone was used to determine the possible mechanism underlying the antinociceptive effects of MTG and 7HMG. In addition, each mouse concurrently underwent measurement of locomotor activity to assess if increases in hotplate response latency were due to non-specific behavioral disruption. The pharmacokinetic-pharmacodynamic (PK/PD) relationship was then evaluated to determine how plasma concentrations of MTG and 7HMG (as both a metabolite and after individual administration) correlate to the measured hotplate latency. The results of this study will give insight into the magnitude of the contribution of 7HMG to the overall pharmacology of MTG.

MATERIALS AND METHODS.

Compounds. MTG was isolated and purified from a kratom alkaloid enriched extract (OPMS, Choice Organics, Los Angeles, CA, USA) as described in previous literature (Avery et al., 2019; Sharma et al., 2019) and was used as the hydrochloride (HCl) salt with a purity \geq 98%. 7HMG (purity \geq 98%) was obtained through semi-synthesis from MTG as previously reported (Maxwell et al., 2020) and used as the freebase. Purity and structural characterization of MTG and 7HMG were established using ¹H proton and ¹³C carbon nuclear magnetic resonance spectroscopy (NMR), ultra-high-performance liquid chromatography-photodiode array detection (UHPLC-PDA), and liquid chromatography high-resolution quadrupole time of flight mass spectrometry (LC-Q-TOF-MS). (-)-Naltrexone hydrochloride (purity \geq 98%), midazolam (purity \geq 98%), phenacetin [purity \geq 98%, internal standard (IS)], and verapamil [purity \geq 98%, (IS)] were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Tween-80°, propylene glycol, and LC-MS grade acetonitrile, methanol, and formic acid were procured from Fisher Scientific (Waltham, MA, USA). Blank pooled mouse plasma was obtained from Innovative Research, Inc. (Novi, MI, USA). Nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt (NADPH) was purchased from MP Biomedicals (Solon, OH, USA). Male and female pooled mouse liver microsomes (MLM) were obtained from XenoTech, LLC (Lenexa, KS, USA).

Formulations. Each test compound and/or vehicle was administered orally (p.o.) by gavage at a dose volume of no more than 10 mL/kg. For the functional studies, each test compound was dissolved in a vehicle consisting of sterile water (HyClone Water for Injection, 1L, Fisher Scientific) containing 5% (v/v) Tween 80[®] and 5% (v/v) propylene glycol to reach behaviorally active doses of test compounds. The formulation or vehicle was filtered with a 0.2-μm pore size syringe filter (Millex-LG, Sigma Aldrich Co.) prior to administration. The dose ranges and pretreatment times were chosen based on preliminary data and published methods (Tanda 2016, Obeng 2021, Behnood 2020, Obeng 2020, Hiranita 2019). For the pharmacokinetic studies, MTG and 7HMG were prepared by dissolving MTG hydrochloride and 7HMG free base in purified water with 3% (v/v) Tween 80[®] to get a freebase equivalent solution of 16.5 and 5.0 mg/mL, respectively.

Instrumentation and Analytical Conditions. ¹H and ¹³C NMR spectra were obtained using Bruker Avance NEO 600 NMR and Bruker Avance II 600 MHz NMR spectrometers operating at 600 MHz in ¹H and 151 MHz in ¹³C (Bruker Co., Billerica, MA, USA). A previously reported ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method validated for the quantification of MTG and 7HMG was used to analyze study samples (Maxwell, 2020). The UPLC-MS/MS was a Waters Acquity Class-I chromatograph coupled with a Xevo TQ-S Micro triple quadrupole mass spectrometer (Waters, Milford, MA, USA).

In brief, a Waters Acquity UPLC BEH C18 column (1.7 μm, 2.1 x 50 mm) fitted with a Vanguard precolumn of the same chemistry, was used with an aqueous mobile phase of 0.1% formic acid in water (A) and an organic mobile phase of acetonitrile (B). Gradient elution was used where 80% A was supplied for 0.5 min and then decreased linearly to 68% up to 2.2 min and then 62% up to 3.5 min after which it was raised back up to 80% where it was maintained until 5.5 min at a flow rate of 0.35 mL/min. The method was updated to a quantitation range of 2-800 ng/mL with a 0.4 μL injection volume. In addition, the method was previously validated in dog plasma (Maxwell et al., 2020) so partial validations were performed for each of the additional matrices (mouse plasma, brain, lung, liver, kidney, and spleen).

For antinociception, a hard black anodized aluminum plate with a built-in digital thermometer (33.1 cm long, 28.8 cm wide, 9.9 cm high, Hot Plate Analgesia Meter, Columbus Instruments, Columbus, OH) was used. A clear acrylic cage (26.7 cm long, 26.7 cm wide, and 31.0 cm high) surrounded the square plate to confine the animal. The temperature was maintained at 52°C and measured to an accuracy of ± 0.1°C. For horizontal locomotor activity, a seamless open field system for mice was used (MED-OFAS-MSU, Med Associates Inc., Fairfax, VT). Med-PC software version 7 (SOF-812, Med Associates Inc., Fairfax, VT) controlled experimental events and provided a record of responses.

Preparation of Calibration Standards and Quality Control Samples. MTG hydrochloride was first dissolved in acetonitrile to create a 1.0 mg/mL free base equivalent of primary stock. 7HMG freebase was dissolved separately in acetonitrile to create an additional 1.0 mg/mL primary stock. Aliquots from these primary stocks were diluted in acetonitrile to create secondary stocks containing 10, 1.0, and 0.1 μg/mL of each compound. These secondary

stocks were then used to create a set of eight working stocks ranging from 25-10000 ng/mL for the preparation of the calibration standards, also in acetonitrile. Quality control (QC) working stocks ranging from 25-8750 ng/mL were created from a different primary stock than the calibration standards.

Sample Processing. Samples were thawed to room temperature for one hour prior to analysis. To prepare blank or study samples for analysis, 25 μ L aliquots of each sample were taken. Samples expected to fall outside the linearity range were diluted 5, 25, or 100 times. To prepare calibration standards, 2.0 μ L of working stock was added to 23 μ L of the appropriate blank matrix. This generated eight standards of 2.0, 10, 50, 100, 200, 400, 600, and 800 ng/mL. The same process was used to generate QCs: the lower limit of quantification (LLOQ, 2.0 ng/mL), low (LQC, 5.0 ng/mL), medium (MQC, 350 ng/mL) and high (HQC, 700 ng/mL) QCs. After spiking, the samples were vortex mixed for five min at 800 rpm. Simple protein precipitation using 100 μ L methanol acidified with 0.05% formic acid containing 25 ng/mL IS was used to extract analytes. The samples were then vortex mixed for five min at 650 rpm before being transferred to a 96-well Millipore 0.45 μ m filter plate and centrifuged at 850 x g for two min at 4°C. The filtrate was then subjected to UPLC-MS/MS analysis. The TargetLynxTM application of MassLynxTM 4.2 was used for data processing (Waters, Milford, MA, USA).

Animals. Adult male and female C57BL/6 mice (weight range 20-30 g) were purchased through Charles River (Wilmington, MA, USA) and group housed in home cages (N=5 per cage for pharmacokinetics studies; N=4 per cage for behavioral studies). Each mouse was acclimated for at least three days to a temperature and humidity-controlled vivarium with a 12-hr light/dark cycle. The temperature, humidity, and light/dark cycle in the experimental rooms were equivalent to those in the vivarium. Food [2918 Teklad Global 18% protein rodent diet (Envigo, Frenchtown, NJ)] and reverse osmosis water was available in the home cage. Study protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Florida, which is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and were written in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.

Pharmacodynamic Studies. All functional experiments were conducted in the light cycle at the same time each day (08:00 to 12:00). The body weight of each mouse (N=4 per sex, per dose) was measured before experiments. In each time course study, the hotplate latency and locomotor activity experiments were conducted sequentially under a within-subject design. A total of 72 mice were used. Each mouse was used only once.

Each mouse was placed on the heated plate and baseline latency was determined manually using a stopwatch (Martin Stopwatch, Martin Sports, Carlstadt, NJ) by trained and experimentally blinded raters. Hotplate latency was measured until the subject jumped, licked, and/or shook the back paws, any deemed toxicity (i.e., seizure) was observed, or up to 30 sec to avoid tissue damage, whichever occurred first. After the measurement of hotplate latency, each mouse was placed singly into the clear acrylic chamber and activity counts were measured over a 5 min period.

Following the determination of the baselines, each mouse orally received either a single dose of MTG or 7HMG, or vehicle and then was returned to the respective home cage. In each mouse, the hotplate response latency and activity counts were measured repeatedly every 30 min up to 240 min after dosing. A 1.0 mg/kg naltrexone dose was administered intraperitoneally (i.p.) five min prior to p.o. administration of the highest doses of MTG or 7HMG. Upon completion of each time-course test, each mouse was euthanized.

Pharmacokinetic and Tissue Distribution Studies. According to the results of the hotplate test, the effective dose to reach 50 percent maximum possible effect (ED_{50}) of each compound was tested in the pharmacokinetic study (165 and 50 mg/kg for MTG and 7HMG, respectively). The first pharmacokinetic study was performed in 40 males and 40 females using a single oral dose of 165 mg/kg MTG. The mice were randomly divided into ten groups of N=4 per sex, per time point with blood samples collected by cheek vein bleed and at the terminal time points for a total of 16 time points (pre-dose, 0.083, 0.25, 0.50, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 12, 18, 24, and 48 hr). Tissue samples were collected at the terminal time points (0.25, 0.50, 1.0, 2.0, 4.0, 6.0, 12, 18, 24, and 48 hr).

Another study was performed with a 50 mg/kg single oral dose of 7HMG in 24 males and 24 females (N=4 per sex, per time point). Blood samples were collected at pre-dose, 0.083, 0.25, 0.50, 0.75, 1.0, 1.5, 2.0, 3.0,

4.0, 5.0, and 6.0 hr, while tissues were collected at the terminal time points only (0.25, 0.5, 1.0, 2.0, 4.0, and 6.0 hr).

Blood samples were collected into heparinized tubes and plasma was separated by centrifugation for 10 min at $850 \times g$ and 4° C. Organs were prepared for analysis by homogenization with aqueous buffer at a ratio of 1:4 organ to buffer. All samples were stored at -80 °C until analysis.

Metabolic Stability of MTG and 7HMG in Mouse Liver Microsomes. The in vitro metabolic stability of MTG and 7HMG was determined using male and female MLM. The incubation mixtures consisted of MLM (1 mg microsomal protein/mL), substrate (1 μ M), and NADPH (1 mM) in a total volume of 0.2 mL potassium phosphate buffer (50 mM, pH 7.4). Midazolam was used as a positive control. Reactions were initiated with the addition of NADPH and kept in an incubator shaker at 37 °C. For negative control, incubations without NADPH were also performed. All incubations were performed in triplicate. Aliquots of 25 μ L each were withdrawn at 0, 5, 10, 15, 30, and 60 min and mixed with 125 μ L of acetonitrile containing IS for the termination of the reaction. The samples were then vortex mixed and filtered through a 0.45 μ m 96-well membrane filtration plate under centrifugation at speed of 850 \times g for 5 min at 4°C. The filtrates were subjected to UPLC-MS/MS analysis.

Data Analysis. Precision and accuracy were evaluated by calculating the percent relative standard deviation (RSD) and the percent bias (%Bias) at each concentration tested (N=6, each concentration), respectively. RSD was calculated using the formula:

$$RSD = \frac{(SD \times 100)}{(Mean)}$$

While the %Bias was calculated using the equation:

Organ concentrations were corrected for residual blood using the following formula (Khor and Mayersohn, 1991; Giudicelli et al., 2004):

$$C_{corrected} = \frac{(C_{measured} - C_{blood} \times W_{blood})}{(1 - W_{blood})}$$

where $C_{measured}$ was the concentration obtained after UPLC/MS-MS analysis, C_{blood} was calculated by multiplying $C_{measured}$ times the blood to plasma partition coefficient (1.0 for MTG and 1.1 for 7HMG in females; 0.9 for both MTG and 7HMG in males, Supp. Table 2) which was determined using previously published methods (Yu et al., 2005). W_{blood} represents the volume of residual blood in the organ relative to the volume of the organ. W_{blood} values for each organ are as follows: Kidney = 0.24, liver = 0.31, lung = 0.50, spleen = 0.17, and brain = 0.03 (Brown et al., 1997). Once corrected, the concentration versus time profiles were generated using Graphpad Prism Version 8 (GraphPad Software, San Diego California, USA) and non-compartmental analysis was performed using the sparse sampling method and linear trapezoidal extrapolation to determine the pharmacokinetic parameters of each compound in plasma and tissues using Phoenix Version 6.4 (Certara, Princeton, NJ, USA).

For the functional studies, all the experimental variables in each figure are shown as mean values [\pm standard error of the mean (SEM)] per groups of subjects as a function of elapsed time after administration. Statistical analyses were conducted using GraphPad Prism version 8 (San Diego, CA) and SigmaPlot version 14.0 (Systat Software Inc., San Jose, CA). Statistical differences were considered significant when a p value was less than 0.05. A one- or two-way (repeated-measures) analysis of variance (ANOVA) followed by *post hoc* Bonferroni t tests was used as appropriate to analyze the effects of elapsed time after administration, dose, or their interactions.

Hotplate latency data in sec was converted to percent maximum possible antinociceptive effect (MPE) with the following equation:

%MPE=
$$\frac{\text{(Test latency value - the baseline latency value)}}{\text{(60 sec - the baseline latency value)}} \times 100$$

The locomotor activity counts of doses of test compounds were normalized to that of vehicle per corresponding time point. When the mean effect of a compound to produce an increase in percent MPE or decrease locomotor activity crossed 50% of vehicle level per time point, the ED_{50} and 95% confidence interval (CI) values in μ mol/kg

were calculated using linear regression (Snedecor and Cochran, 1967), where slopes were allowed to vary, according to Tallarida (Tallarida, 2002). The potency ratio was derived from the ED_{50} (95% CIs) value for MTG divided by that for 7HMG. If the 95% CIs of the ED_{50} values did not overlap, or the potency ratio of the compounds did not include one, the compounds were considered to have significantly different potencies. To compare the ED_{50} (95% CIs) values in μ mol/kg, molecular weights for MTG (MTG HCl) and 7HMG used were 398.50 (434.96) and 414.50 g/mol, respectively.

The *in vitro* elimination half-life $(t_{1/2})$ was determined using the following equation:

$$t_{1/2} = \frac{-0.693}{k}$$

where k is the slope of the line obtained by plotting natural logarithmic of the percentage of compound remaining versus time. The amount of 7HMG produced in MLM after MTG incubation was also quantified and the metabolite to parent ratio was determined at 60 minutes by dividing the concentration of 7HMG formed by the concentration of MTG incubated (1 µM).

The PK/PD relationship for both MTG and 7HMG was examined by fitting the data to a population PK/PD model using Monolix (Monolix version 2020R1. Antony, France: Lixoft SAS, 2020). All parameters were fitted with the observed data and simulations were performed at various doses to validate the models.

RESULTS.

Method Validation. Supp. Table 1 shows the results of all partial validations. The calibration curves for each matrix type were considered acceptable if the correlation coefficient (r^2) was greater than 0.99. QC samples were prepared for each run and fell within the limits of \pm 20% at the LLOQ and \pm 15% at the LQC, MQC, and HQC as required by the FDA Guidelines for Bioanalytical Method Validation (FDA, 2018).

Antinociception and Locomotor Activity. Baseline values for hotplate response latency (approximately 11 sec) and locomotor activity counts (approximately 825 counts) were statistically comparable across all groups regardless of sex, dose, or their interaction (F values \leq 3.63; P values \geq 0.062, Figures 2-5 and Supp. Table 3). Thus, data from

females and males was combined and is shown in Figures 2 and 4. Following vehicle administration (filled circles), MPEs were stably low (Figure 2, upper left); however, activity counts were gradually decreased over time and stabilized at less than 100 counts 120 min after vehicle administration (Figure 2, lower left).

In addition to vehicle, effects of MTG and 7HMG on MPE and locomotor activity counts are shown in Figure 2. MTG dose- and time-dependently produced significant increases in MPE (Figure 2, top left; Supp. Table 4). Each gray symbol in Figure 2 indicates a significant difference from vehicle per corresponding time point (Supp. Table 4). The MTG dose of 92 mg/kg (open squares) was inactive whereas the increases in MPE and duration of action were greater in the 293 mg/kg MTG dose than the 163 mg/kg MTG dose (triangles downward and upward, respectively). There was no significant effect of sex on MPE (Supp. Table 4). The ED₅₀ (95% CIs) value of MTG to increase the percentage of MPE was 340 (262-400) μmol/kg at 90 min after administration (Table 1). In addition, activity counts (Figure 2, lower left, Supp. Table 4) were significantly increased by 163 mg/kg MTG at 60 and 90 min after administration (triangles upward) but decreased by 293 mg/kg MTG at 30 min after administration (triangles downward). There was no significant effect of sex on activity counts (Supp. Table 4).

As with MTG, 7HMG dose- and time-dependently produced significant increases in MPE (Figure 2, top right; Supp. Table 4); however, the duration of action of 7HMG was shorter than that of MTG. For example, at 240 min after administration, the MPE was $94.1 \pm 5.1\%$ and $7.8 \pm 4.8\%$ for MTG and 7HMG, respectively. In contrast to MTG, there was a significant effect of sex on percentage of MPEs (Supp. Table 4). After the 30 min time point, increases in MPE were significantly greater in males than females (Figure 3, Supp. Table 4). The duration of antinociceptive action of 7HMG was longer in males than females (Figure 3). The ED₅₀ (95% CIs) values of 7HMG to increase the MPE was 121 (114-152), 122 (111-158), and 119 (108-154) μ mol/kg at 30 min after administration in a combination of females and males, females only, and males only (Table 1). The antinociceptive potency ratio (95% CIs) of 7HMG relative to MTG was 2.81 (1.72-3.51) (Table 1). Activity counts (Figure 2, lower right) were only increased by 7HMG; the maximum increase in activity counts 60 min

after administration was approximately 200 counts per minutes higher in 100 mg/kg 7HMG than in 163 mg/kg MTG.

Naltrexone, a MOR antagonist, was used to assess a pharmacological mechanism underlying the effects of MTG and 7HMG (Figure 4). Naltrexone fully antagonized the antinociceptive effects of 293 mg/kg MTG (Figure 4, upper left; Supp. Table 4). There were significant effects of sex alone and a combination of sex with dose on MPE (Supp. Table 4). However, there was no significant interaction of dose with time (Supp. Table 4). Thus, there is no gray symbol in percentage of MPEs (Supp. Table 4). Naltrexone also fully antagonized the decrease in activity counts 30 min after administration of 100 mg/kg 7HMG (Figure 4, lower left; Supp. Table 4). There was a significant effect of sex on activity counts; however, there was no significant interaction of sex with dose or time (Supp. Table 4). As with MTG, naltrexone fully antagonized the increases in MPE and activity counts following administration of 100 mg/kg 7HMG regardless of sex (Figures 4 and 5, lower left; Supp. Table 4).

Analysis of Pharmacokinetic Data. The *in vitro* microsomal half-lives of MTG and 7HMG were determined after 60 min incubation with male and female MLM. The microsomal stability of MTG was found to be greater in females $(0.52 \pm 0.01 \text{ hr})$ than males $(0.44 \pm 0.01 \text{ hr})$. The stability of 7HMG was similar in males and females $(0.94 \pm 0.01 \text{ and } 0.97 \pm 0.03, \text{ respectively})$. There was no conversion of 7HMG to MTG observed after 60 min incubation of 7HMG with male or female MLM. The percent of 7HMG formed after incubation of MTG in MLM was 12 and 10 in males and females, respectively.

All plasma and tissue samples following a single oral administration of MTG 165 mg/kg were analyzed for MTG and 7HMG content. The tissue concentrations were corrected for residual blood volume and once corrected, mean plasma/tissue concentration-time curves were constructed for each compound of interest as seen in Figure 6 and Supp. Figure 1. The results of the non-compartmental analysis for brain and plasma MTG and 7HMG concentration following a 165 mg/kg dose of MTG are shown in Table 3. MTG was distributed in the following order: liver > kidney > lung > spleen > brain (Table 3, Supp. Table 5). 7HMG following MTG administration was distributed in decreasing order of liver > kidney > spleen > lung > brain; similar to MTG

distribution with a marked difference in lung concentrations (Table 2, Supp. Table 5). The organ to plasma exposure ratios for MTG and 7HMG in the lung were 15.9 and 1.5, respectively (Supp. Table 5).

Figure 7 and Table 3 show the mean plasma and brain concentration-time curves and the results of the non-compartmental analysis for 7HMG following a single oral dose of 50 mg/kg. 7HMG was distributed in the following descending order: liver > kidney > spleen > lung > brain (Figure 7, Supp. Figure 2). The tissue distribution followed the same order as that seen for 7HMG distribution after the MTG dose (Supp. Table 6).

PK/PD Modeling. For MTG the PK/PD relationship was best characterized as a direct-link model where the effect (E) is determined using the Hill equation:

$$E = E_0 + \frac{E_{max} \times C^{\gamma}}{EC_{50}^{\gamma} + C^{\gamma}}$$

where E_0 is the baseline effect after vehicle administration, E_{max} is the maximum effect, EC_{50} is the concentration at which 50% of the maximum effect is seen, and C is the concentration of compound (Derendorf and Meibohm, 1999). The factor gamma (γ) accounts for the sigmoid nature of the drug effect. The parameters of the models developed for MTG and 7HMG along with the likelihood distribution and error for both can be seen in Supp. Table 7. The plots describing the goodness of fit of each model can be seen in Supp. Figure 3. The PK/PD model for MTG was a linear, two compartment pharmacokinetic model with a direct pharmacodynamic effect. Sex was added as a covariate for clearance. The error model used was constant for MPE and proportional for plasma concentration. The predicted effect versus time were plotted for doses of 92 and 293 mg/kg MTG and this was compared to the observed effect values (Figure 8A).

The model that was developed for 7HMG was a linear one compartment model with an effect compartment equilibration rate constant (k_{e0}) in order to describe the time delay between the measured concentrations and the observed effect. This changes the Hill equation to:

$$E = E_0 + \frac{E_{max} \times C_e^{\gamma}}{EC_{e50}^{\gamma} + C_e^{\gamma}}$$

where C_e is the concentration in the effect compartment (Holford and Sheiner, 1981). Sex was added as a covariate for γ , the concentration to produce 50% of the maximum effect (EC₅₀), the effect compartment equilibration rate contant (k_{e0}), and the volume of distribution (V/F). The error model used for 7HMG was constant for MPE and proportional for plasma concentration. Meanwhile, the predicted effect versus time for 32 and 100 mg/kg 7HMG was also compared to the observed values to validate the model (Figure 8B). For each, the model with the lowest -2 log likelihood and least error was selected as the best fit to describe the observed data. The interindividual variability of both models was found to be high, but this can be attributed to the small sample sizes. Due to this, the population PK/PD model developed for MTG and 7HMG will be useful to provide a qualitative assessment of effect after different doses, but quantitative assessments will require more input parameters to further validate the model.

DISCUSSION.

The primary goal of this study was to assess the contribution of 7HMG to the antinociceptive effects of MTG following oral administration of MTG in mice. When individually administered orally based on ED₅₀ values, both MTG and 7HMG significantly increased the hotplate response latency at doses of 163 mg/kg and 56 mg/kg, respectively. The apparent increases in hotplate response latency were not due to nonspecific behavioral disruption because the increases in hotplate response latency were present without decreases in locomotor activity counts. Based on the antinociceptive potency ratios, 7HMG was 2.8-fold more potent than MTG to produce the antinociceptive effects. Using the antinociceptive doses of MTG and 7HMG, the pharmacokinetic studies were conducted. The pharmacokinetic studies found that the concentration of 7HMG present in the brain as a metabolite of MTG [maximum concentration (C_{max}) lower than concentrations found 4 hr post equianalgesic 7HMG dose] cannot account for the antinociception observed after MTG administration. Interestingly, the antinociceptive effects of MTG were fully reversed by the opioid receptor agonist naltrexone, indicating that the effect of MTG is in part mediated by MOR despite its lower affinity for the receptor.

The results of the tissue distribution analysis indicate that MTG is a perfusion limited compound as the calculated concentrations followed the blood flow to organs in mice (liver > kidney > brain > lung > spleen). The exception was the brain, which can be explained by the selectivity of the blood brain barrier (BBB). The organ to plasma exposure ratio for MTG in the brain was 2.2 and 1.8 in males and females, respectively, indicating that MTG has high BBB penetration. MTG was also rapidly distributed into the brain, as well as other organs, with time to the maximum concentration of 0.25 to 0.5 hr for all organs. The mean residence time (MRT), the average amount of time a molecule resides in the body, of MTG was 4.1-5.5 hr, indicating there is no accumulation of MTG after a single oral dose.

The metabolite to parent exposure after MTG administration was 2%-9% in all organs except the lungs where it was only 0.3%. The MRT of 7HMG after MTG administration was 2.4-3.1 hr. The C_{max} of 7HMG achieved in the brain as a metabolite was $0.6-0.7~\mu g/g$ with an overall exposure of 1.7-2.2 hr* $\mu g/g$. Also, 7HMG as a metabolite showed adequate BBB penetration with a brain to plasma ratio of 0.6 in females and 1.5 in males. The brain to plasma ratios demonstrated in this study are higher than the previously reported values but this difference may be explained by a single time point versus the entire time course of 7HMG as well as alternate routes of administration. The previously reported brain to plasma ratios of MTG and 7HMG after subcutaneous administration of MTG at two time points (15 and 60 min) were 1.0 and 0.2, respectively, in 129S1 mice (Kruegel et al., 2019).

It has been reported in the literature that 7HMG metabolizes to MTG (Manda et al., 2014), but no quantifiable MTG was found in any samples following oral administration of 50 mg/kg 7HMG indicating that the quantifiable conversion of 7HMG to MTG did not occur in mice in this study. These results are supported by the *in vitro* microsomal data as well as the results of a PK study in female beagle dogs (Maxwell et al., 2021). The MRT of 7HMG after 7HMG oral dose was 1.2-2.0 hr in the various organs, which is less than the MRT of 7HMG after MTG administration. Independent of MTG, 7HMG has a shorter residence time in the body but when present as a metabolite of MTG, it remains in the tissues longer, indicating that the rate of elimination of 7HMG as a metabolite is governed by its formation.

Compared to MTG, 7HMG is less perfused into tissues, which may be due to the differences in lipophilicity of the compounds, resulting in the lower ability of 7HMG than that of MTG to cross through lipid bilayers. The reported $logP_{Oct}$ values for MTG and 7HMG were 4.1 and 1.7, respectively (Yusof et al., 2019). The organ to plasma ratios of 7HMG were 2.5- to 5.0-fold lower after a 50 mg/kg 7HMG dose as compared to a 165 mg/kg MTG dose, suggesting that MTG may have some influence on the ability of 7HMG to move freely into and out of tissues and/or MTG metabolism occurs in these organs. The MRT of each compound coincides with the functional results where the peak antinociceptive effects of MTG were present up to 4 hr post dose (MRT 4.1-5.5 hr) while 7HMG effects were only seen up to 1-2 hr post dose (MRT 1.2-2.0 hr). These results contrast with the *in vitro* microsomal data generated where 7HMG was found to be twice as stable as MTG (approximately 1 hr vs 0.5 hr, respectively) in both male and female MLM. This would suggest that 7HMG undergoes extrahepatic elimination and/or phase II metabolism. The C_{max} of 7HMG achieved in the brain after administration of 50 mg/kg 7HMG was 9.8 µg/g in males and 3.6 µg/g in females, 16- and 5- fold higher than the C_{max} as a metabolite of MTG.

Behavioral differences were noted in mice dosed either with MTG or 7HMG. In the MTG dosed group, no observable behaviors were noted while in the 7HMG dosed group the Straub tail response was seen up to 4 hr post dose. This response has been reported to be related to MOR 2 activation which is associated with the adverse effects associated with opioid abuse (Pasternak, 1988; Nath et al., 1994). The same behavior was not seen even after the 294 mg/kg MTG dose, indicating that the amount of 7HMG generated as a metabolite of MTG is either insufficient to produce the response or MTG may antagonize the 7HMG-induced Straub tail response. This is supported by *in vitro* evidence, as MTG antagonized activity of 7HMG at human MOR using a [35S]GTPγS functional assay (Obeng et al., 2021).

Females had lower exposure of both MTG and 7HMG which helps to explain their lower overall MPE results in behavioral assays. Sex differences in pharmacokinetics of animal models are common (Czerniak, 2001) but do not always lead to behavioral differences. For example, with MTG no statistically significant differences were observed in MPE after MTG administration despite a 2-fold difference in overall brain exposure.

Meanwhile, a 1.4-fold difference in exposure (in both brain and plasma) of 7HMG after 7HMG administration led to statistically significant differences in MPE > 30 min after administration between males and females. Using the PK/PD model to simulate 250 subjects receiving the ED₅₀, the EC₅₀ of 7HMG was estimated to be 5.3 μ g/mL for females, while for males it was only 3.2 μ g/mL. This difference in sensitivity between sexes has been seen in rodent models of pain when researching typical opioid agonists like morphine (Craft et al., 2001). Specifically, in tests of hot plate antinociception in mice, males have been found to be more sensitive to morphine than females (Kavaliers and Innes, 1990; Kavaliers and Innes, 1992). Suggested mechanisms of sex variations include hormonal, genetic, and/or receptor density-based differences (Loyd et al., 2008; Lee and Ho, 2013; Liu et al., 2018). The differences in response to MTG and 7HMG by male versus female mice seen in this study further the assertion that 7HMG acts as a typical MOR agonist while MTG acts on MOR atypically.

It is important to note that all the pharmacokinetic values in the present study are reported as the total concentration of the compound (fraction bound plus fraction unbound) while only the fraction unbound is available for pharmacological action. Previously, the unbound fraction of MTG and 7HMG in the rat brain has been reported as 0.027 ± 0.002 and 0.26 ± 0.04 , respectively, while the unbound fraction in other tissues is not available in the literature (Yusof et al., 2019).

In summary, here we showed that the amount of 7HMG present in the brain after MTG administration alone cannot account for the functional activity of MTG, refuting an earlier study (Kruegel et al., 2019). In the present study, the exposure of 7HMG in the brain after an antinociceptive dose of MTG was 4.0 -fold and 3.7-fold less in males and females, respectively, than that after an antinociceptive dose of 7HMG. The C_{max} of 7HMG in the brain achieved as a metabolite of MTG was similar to concentrations seen 4 hr post dose of 7HMG where MPE was < 10%.

Conclusions. The results of this study give important information towards understanding the overall pharmacology of MTG. The 7HMG exposure generated from the metabolism of MTG administration cannot solely be responsible for the analgesic effects of MTG. Species differences in metabolism, brain penetration, and free fraction of drug must all be considered when translating these results to higher order species. Though these

results provide valuable information about a preclinical rodent model, species differences in the fraction of MTG metabolized to 7HMG have been reported. In female beagle dogs, the AUC ratio of 7HMG to MTG was 13%, 1.4-fold greater than that found in female mice indicating that concentrations of free 7HMG may be greater in dogs and have more potential to influence the overall pharmacology of MTG (Maxwell et al., 2020). Combining the population PK/PD approach with physiologically based pharmacokinetic modeling that considers the aforementioned species and sex differences uncovered in this study will be helpful in translating preclinical results into first in human dose recommendations while also contributing to the continued evaluation of MTG.

Downloaded from dmd.aspetjournals.org at ASPET Journals on April 19, 2024

ACKNOWLEDGEMENTS

The authors would like to acknowledge Dr. Bonnie A. Avery and her contributions to the success of this work

group.

AUTHORSHIP CONTRIBUTIONS.

Participated in research design: Berthold, Kamble, Kanumuri, Sharma, Hiranita, McMahon, and McCurdy

Conducted experiments: Berthold, Kamble, Kanumuri, Kuntz, Senetra, Restrepo, Patel, Ho, and Sharma

Contributed new reagents or analytic tools: Mottinelli, León, and McCurdy

Performed data analysis: Berthold, Kamble, Kanumuri, Kuntz, Hiranita, and Sharma

Wrote or contributed to the writing of the manuscript: Berthold, Kamble, Kanumuri, Senetra, Sharma, Kuntz,

Mottinelli, León, Hiranita, McMahon, and McCurdy

FOOTNOTES

This study was supported by the National Institutes of Health National Institute of Drug Abuse [Grants UG3

DA048353, UH3 DA048353, R01 DA047855], the University of Florida Clinical and Translational Science

Institute, which is supported in part by the National Institutes of Health National Center for Advancing

Translational Sciences [UL1TR001427], and the University of Florida Foundation and University of Florida

Department of Pharmacodynamics Funding.

Graphical abstract created with Biorender.com.

#Current address: Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of

South Carolina, Columbia, SC, USA

Conflicts of Interests or Disclaimers: None

Reprint requests may be sent to: Drs. Abhisheak Sharma or Christopher R. McCurdy, College of Pharmacy,

University of Florida, Stetson Medical Science Building, 1345 Center Drive, PO Box 100485 Gainesville, FL

32610 Emails: asharma1@cop.ufl.edu or cmccurdy@cop.ufl.edu, respectively.

REFERENCES

- Avery BA, Boddu SP, Sharma A, Furr EB, Leon F, Cutler SJ, and McCurdy CR (2019) Comparative Pharmacokinetics of Mitragynine after Oral Administration of Mitragyna speciosa (Kratom) Leaf Extracts in Rats. *Planta Med* **85:**340-346.
- Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, and Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. *Toxicol Ind Health* **13:**407-484.
- Chear NJ, Leon F, Sharma A, Kanumuri SRR, Zwolinski G, Abboud KA, Singh D, Restrepo LF, Patel A, Hiranita T, Ramanathan S, Hampson AJ, McMahon LR, and McCurdy CR (2021) Exploring the Chemistry of Alkaloids from Malaysian Mitragyna speciosa (Kratom) and the Role of Oxindoles on Human Opioid Receptors. *J Nat Prod*.
- Craft RM, Tseng AH, McNiel DM, Furness MS, and Rice KC (2001) Receptor-selective antagonism of opioid antinociception in female versus male rats. *Behav Pharmacol* **12:**591-602.
- Czerniak R (2001) Gender-based differences in pharmacokinetics in laboratory animal models. *Int J Toxicol* **20:**161-163.
- Derendorf H and Meibohm B (1999) Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. *Pharm Res* **16:**176-185.
- Eastlack SC, Cornett EM, and Kaye AD (2020) Kratom-Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review. *Pain Ther* **9:**55-69.
- Ellis CR, Racz R, Kruhlak NL, Kim MT, Zakharov AV, Southall N, Hawkins EG, Burkhart K, Strauss DG, and Stavitskaya L (2020) Evaluating kratom alkaloids using PHASE. *PLoS One* **15**:e0229646.
- FDA (2018) Bioanalytical Method Validation Guidance for Industry (Administration FaD ed, Silver Spring, MD. FDA (2021) FDA Adverse Events Reporting System (FAERS) (Administration FaD ed, Silver Spring, MD.
- Giudicelli C, Dricot E, Moati F, Strolin-Benedetti M, and Giudicelli JF (2004) Is it important to correct apparent drug tissue concentrations for blood contamination in the dog? *Fundam Clin Pharmacol* **18:**281-286.
- Hemby SE, McIntosh S, Leon F, Cutler SJ, and McCurdy CR (2019) Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. *Addict Biol* **24:**874-885.
- Hiranita T, Leon F, Felix JS, Restrepo LF, Reeves ME, Pennington AE, Obeng S, Avery BA, McCurdy CR, McMahon LR, and Wilkerson JL (2019) The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats. *Psychopharmacology (Berl)* **236:**2725-2734.
- Holford NH and Sheiner LB (1981) Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. *Clin Pharmacokinet* **6:**429-453.
- Kamble SH, Sharma A, King TI, Leon F, McCurdy CR, and Avery BA (2019) Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom). *Xenobiotica* **49:**1279-1288.
- Kavaliers M and Innes D (1992) Sex differences in the effects of neuropeptide FF and IgG from neuropeptide FF on morphine- and stress-induced analgesia. *Peptides* **13:**603-607.
- Kavaliers M and Innes DG (1990) Developmental changes in opiate-induced analgesia in deer mice: sex and population differences. *Brain Res* **516**:326-331.

- Khor SP and Mayersohn M (1991) Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. I. Theoretical considerations. *Drug Metab Dispos* **19:**478-485.
- Kruegel AC, Uprety R, Grinnell SG, Langreck C, Pekarskaya EA, Le Rouzic V, Ansonoff M, Gassaway MM, Pintar JE, Pasternak GW, Javitch JA, Majumdar S, and Sames D (2019) 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects. *ACS Cent Sci* **5:**992-1001.
- Lee CW and Ho IK (2013) Sex differences in opioid analgesia and addiction: interactions among opioid receptors and estrogen receptors. *Mol Pain* **9:**45.
- Liu A, Zhang H, Qin F, Wang Q, Sun Q, Xie S, Wang Q, Tang Z, and Lu Z (2018) Sex Associated Differential Expressions of the Alternatively Spliced Variants mRNA of OPRM1 in Brain Regions of C57BL/6 Mouse. *Cell Physiol Biochem* **50:**1441-1459.
- Loyd DR, Wang X, and Murphy AZ (2008) Sex differences in micro-opioid receptor expression in the rat midbrain periaqueductal gray are essential for eliciting sex differences in morphine analgesia. *J Neurosci* **28:**14007-14017.
- Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, and Boyer EW (2016) Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine. *J Med Toxicol* **12:**341-349.
- Manda VK, Avula B, Ali Z, Khan IA, Walker LA, and Khan SI (2014) Evaluation of in vitro absorption, distribution, metabolism, and excretion (ADME) properties of mitragynine, 7-hydroxymitragynine, and mitraphylline. *Planta Med* **80:**568-576.
- Matsumoto K, Mizowaki M, Suchitra T, Murakami Y, Takayama H, Sakai S, Aimi N, and Watanabe H (1996) Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. *Eur J Pharmacol* **317:**75-81.
- Maxwell EA, King TI, Kamble SH, Raju KSR, Berthold EC, Leon F, Avery BA, McMahon LR, McCurdy CR, and Sharma A (2020) Pharmacokinetics and Safety of Mitragynine in Beagle Dogs. *Planta Med* **86:**1278-1285.
- Maxwell EA, King TI, Kamble SH, Raju KSR, Berthold EC, Leon F, Hampson A, McMahon LR, McCurdy CR, and Sharma A (2021) Oral Pharmacokinetics in Beagle Dogs of the Mitragynine Metabolite, 7-Hydroxymitragynine. *Eur J Drug Metab Pharmacokinet* **46:**459-463.
- Nath C, Gupta MB, Patnaik GK, and Dhawan KN (1994) Morphine-induced straub tail response: mediated by central mu2-opioid receptor. *Eur J Pharmacol* **263**:203-205.
- Obeng S, Kamble SH, Reeves ME, Restrepo LF, Patel A, Behnke M, Chear NJ, Ramanathan S, Sharma A, Leon F, Hiranita T, Avery BA, McMahon LR, and McCurdy CR (2020) Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids. *J Med Chem* **63:**433-439.
- Obeng S, Wilkerson JL, Leon F, Reeves ME, Restrepo LF, Gamez-Jimenez LR, Patel A, Pennington AE, Taylor VA, Ho NP, Braun T, Fortner JD, Crowley ML, Williamson MR, Pallares VLC, Mottinelli M, Lopera-Londono C, McCurdy CR, McMahon LR, and Hiranita T (2021) Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for mu-Opioid Receptor and Opioid-Like Behavioral Effects in Rats. *J Pharmacol Exp Ther* 376:410-427.
- Pasternak GW (1988) Multiple morphine and enkephalin receptors and the relief of pain. *JAMA* **259:**1362-1367. Sharma A, Kamble SH, Leon F, Chear NJ, King TI, Berthold EC, Ramanathan S, McCurdy CR, and Avery BA (2019) Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry. *Drug Test Anal* **11:**1162-1171.
- Sharma A and McCurdy CR (2021) Assessing the therapeutic potential and toxicity of Mitragyna speciosa in opioid use disorder. *Expert Opin Drug Metab Toxicol* **17:**255-257.
- Singh D, Yeou Chear NJ, Narayanan S, Leon F, Sharma A, McCurdy CR, Avery BA, and Balasingam V (2020) Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users. *J Ethnopharmacol* **249:**112462.
- Snedecor GW and Cochran WG (1967) Statistical methods. Iowa State University Press, Ames,.
- Tallarida RJ (2002) The interaction index: a measure of drug synergism. Pain 98:163-168.

- Varadi A, Marrone GF, Palmer TC, Narayan A, Szabo MR, Le Rouzic V, Grinnell SG, Subrath JJ, Warner E, Kalra S, Hunkele A, Pagirsky J, Eans SO, Medina JM, Xu J, Pan YX, Borics A, Pasternak GW, McLaughlin JP, and Majumdar S (2016) Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit beta-Arrestin-2. *J Med Chem* **59**:8381-8397.
- Veltri C and Grundmann O (2019) Current perspectives on the impact of Kratom use. *Subst Abuse Rehabil* **10:**23-31.
- Yu S, Li S, Yang H, Lee F, Wu JT, and Qian MG (2005) A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. *Rapid Commun Mass Spectrom* **19:**250-254.
- Yue K, Kopajtic TA, and Katz JL (2018) Abuse liability of mitragynine assessed with a self-administration procedure in rats. *Psychopharmacology (Berl)* **235:**2823-2829.
- Yusof SR, Mohd Uzid M, Teh EH, Hanapi NA, Mohideen M, Mohamad Arshad AS, Mordi MN, Loryan I, and Hammarlund-Udenaes M (2019) Rate and extent of mitragynine and 7-hydroxymitragynine blood-brain barrier transport and their intra-brain distribution: the missing link in pharmacodynamic studies. *Addict Biol* **24**:935-945.

LEGENDS FOR FIGURES

Figure 1. Chemical structures of MTG (left) and 7HMG (right).

Figure 2. Effects of MTG and 7HMG on hotplate response latency and locomotor activity counts in mice.

Abscissae: Baseline and elapsed time after oral administration in minutes; baseline values are shown for reference.

Upper left ordinates: Baseline hotplate response latency in second. Upper right ordinates: Percentage of MPE.

Lower left ordinates: Activity counts for five minutes immediately after each measurement of hotplate response

latency. Left panels: Vehicle (filled circles), and 92, 163, and 293 mg/kg MTG (squares, upward triangles, and

downward triangles, respectively). Right panels: Vehicle (filled circles), and 32, 56, and 100 mg/kg 7HMG

(squares, upward triangles, and downward triangles, respectively). The data for vehicle were the same across left

and right panels. Each point represents the mean ± SEM (4 mice per sex). Each gray symbol indicates a

significant difference from vehicle per corresponding time point.

Figure 3. Effects of sex on the antinociceptive effects of 7HMG. Abscissae: Baseline and elapsed time after oral

administration in minutes. Left ordinates: Baseline hotplate response latency in second. Right ordinates:

Percentage of MPE. Left, middle and right panels: 32, 56, and 100 mg/kg 7HMG, respectively. Females (open

diamonds) and males (filled squares). Each point represents the mean \pm SEM. The hot plate was maintained at 52

± 0.1°C. Following the baseline measurement, one of 7HMG doses was administered p.o. Each gray symbol

indicates a significant difference from vehicle per corresponding time point. See Table S3 for details of statistical

analyses. Note that the antinociceptive effects of 7HMG lasted longer in males than females.

Figure 4. Effects of MTG and 7HMG on hotplate response latency and locomotor activity counts in the presence

of the opioid receptor antagonist naltrexone. Abscissae: Baseline and elapsed time after oral administration in

minutes. Upper left ordinates: Baseline hotplate response latency in second. Upper right ordinates: Percentage of

MPE. *Lower left ordinates*: Activity counts for five minutes immediately after each measurement of hotplate response latency. *Left panels*: Vehicle (filled circles), and 293 mg/kg MTG in the absence and presence of naltrexone (downward triangles and diamonds, respectively). *Right panels*: Vehicle (filled circles), 100 mg/kg 7HMG in the absence and presence of naltrexone (downward triangles and diamonds, respectively). The data for vehicle were the same ones in Figure 2. Each symbol represents the mean ± SEM (4 mice/sex). Each gray symbol indicates a significant difference from vehicle per corresponding time point.

Figure 5. Effects of sex on the antinociceptive effects of 100 mg/kg 7HMG in the absence and presence of naltrexone. *Abscissae*: Baseline and elapsed time after oral administration in minutes. *Left ordinates*: Baseline hotplate response latency in second. *Right ordinates*: Percentage of MPE. *Left and right panels*: Females and males, respectively. Vehicle (filled circles), 100 mg/kg 7HMG in the absence and presence of naltrexone (downward triangles and diamonds, respectively). Each point represents the mean ± SEM (4 mice). Each gray symbol indicates a significant difference from vehicle per corresponding time point.

Figure 6. Mean plasma (μ g/mL) and brain (μ g/g of wet tissue) concentration-time curves for MTG (A) and 7HMG (B) following a single oral dose of 165 mg/kg MTG in male and female mice. Each symbol represents the mean (N=4) and error bars represent the SD.

Figure 7. Mean plasma (μ g/mL) and brain (μ g/g of wet tissue) concentration-time curves for 7HMG following a single oral dose of 50 mg/kg MTG in male and female mice. Each symbol represents the mean (N=4) and error bars represent the SD.

Figure 8. Simulation of effect versus time using the developed PK/PD model for doses of 92, 163, and 293 mg/kg MTG (A) and 32, 56, and 100 mg/kg 7HMG (B). Predicted error (dashed lines) represents the 95% CI (N= 25 subjects per sex, per simulation). Error bars on observations represent the SEM (N=4 per time point).

TABLES

Table 1 ED₅₀ (95% CIs) values in μ mol/kg for the antinociceptive and activity-decreasing effects of MTG and 7HMG in mice as shown in Figures 2 and 3. For the MPEs, the ED₅₀ (95% CIs) value was calculated at the time point where the highest dose of MTG or 7HMG produced the 100% MPE as well as respective intermediate doses produced the highest MPEs (i.e. 90 and 30 min, respectively). For the activity-decreasing effects, only the 30 min time point for MTG was eligible for the calculation of ED₅₀ (95% CIs) value. Each sample size is four mice per sex per time points. The potency ratio was derived from the ED₅₀ value for MTG divided by that for 7HMG. To obtain the ED₅₀ (95% CIs) values, molecular weights for MTG and 7HMG used were 398.5 and 414.2 g/mol, respectively.

Compound	ED ₅₀ (95% CIs)			
	MPE	Decrease in Locomotor		
		Activity Counts		
MTG (males and	340 (262 - 400)	384 (255 — 487) @ 30		
females)	@ 90 min	min		
7HMG (males and	121 (114 — 152)	Not determined		
females)	@ 30 min			
7HMG (females)	122 (111 - 158)	Not determined		
	@ 30 min			
7HMG (males)	119 (108 - 154)	Not determined		
	@ 30 min			
Potency Ratio (males	2.81 (1.72 - 3.51)	Not applicable		
and females)				

Table 2. Pharmacokinetic parameters of MTG and 7HMG in plasma and brain following a single oral dose of 165 mg/kg MTG in male and female mice. C_{max} : the maximum concentration [plasma (μ g/mL) and brain (μ g/g of wet tissue)], T_{max} : time to reach maximum concentration, AUC_{0-48} : area under the curve (exposure), MRT: mean residence time of a drug molecule in the body, AUC_{organ}/AUC_{plasma} : organ to plasma exposure ratio, AUC_{7HMG}/AUC_{MTG} : ratio of metabolite to parent.

	MTG			7HMG				
Parameter	Males		Females		Males		Females	
	Plasma	Brain	Plasma	Brain	Plasma	Brain	Plasma	Brain
C _{max} (µg/mL	12.5	35.5	6.8	11.5	0.6	0.6	0.9	0.7
or µg/g)								
T _{max} (hr)	0.25	0.25	0.5	0.5	0.5	0.25	0.5	0.5
AUC ₀₋₄₈								
(hr*μg/mL	52.7	114.8	30.8	55.5	1.4	2.2	2.9	1.7
or hr*µg/g)								
MRT (hr)	5.5	4.1	4.1	5.4	3.1	2.9	2.7	3.3
$\frac{AUC_{organ}}{AUC_{plasma}}$	-	2.2	-	1.8	-	1.6	-	0.6
$\frac{AUC_{7HMG}}{AUC_{MTG}}$	-	-	-	-	0.03	0.02	0.09	0.03

Table 3. Pharmacokinetic parameters of 7HMG in plasma and brain following a single oral dose of 50 mg/kg 7HMG in male and female mice. C_{max} : the maximum concentration [plasma (μ g/mL) and brain (μ g/g of wet tissue)],)], T_{max} : time to reach maximum concentration, AUC_{0-8} : area under the curve (exposure), MRT: mean residence time of a drug molecule in the body, AUC_{organ}/AUC_{plasma} : organ to plasma exposure ratio.

	7HMG					
Parameter	M	ale	Female			
	Plasma	Brain	Plasma	Brain		
C _{max} (μg/mL or μg/g)	10.3	9.8	6.4	3.6		
T _{max} (hr)	0.25	0.25	0.08	0.25		
AUC ₀₋₈ (hr*μg/mL or hr*μg/g)	15.2	8.9	10.5	6.3		
MRT (hr)	1.7	1.2	2.0	1.8		
AUC _{organ} AUC _{plasma}	-	0.6	-	0.6		

Figure 1

Figure 2




Figure 3




Figure 4






Figure 5





Elapsed Time after Oral 7HMG Administration (Minutes)

Figure 6






Figure 7





Figure 8



SUPPLEMENTAL MATERIALS

The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study

Erin C. Berthold¹, Shyam H. Kamble^{1,2}, Kanumuri S. Raju^{1,2}, Michelle A. Kuntz¹, Alexandria S. Senetra¹, Marco Mottinelli³, Francisco León^{3,#}, Luis F. Restrepo⁴, Avi Patel⁴, Nicholas P. Ho⁴, Takato Hiranita⁴, Abhisheak Sharma^{1,2*}, Lance R. McMahon⁴, Christopher R. McCurdy^{1,2,3*}

¹Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA

²Translational Drug Development Core, Clinical and Translational Science Institute, University of Florida, Gainesville, FL, USA

³Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA

⁴Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA

Reprint requests may be sent to: Drs. Abhisheak Sharma or Christopher R. McCurdy, College of Pharmacy, University of Florida, Stetson Medical Science Building, 1345 Center Drive, PO Box 100485 Gainesville, FL 32610 Emails: asharma1@cop.ufl.edu or cmccurdy@cop.ufl.edu, respectively.

Table of Contents	Page/s
Table S1. Validation parameters of UPLC/MS-MS method implemented for the analysis of	3-4
MTG and 7HMG in various biomatrices	
Table S2. Blood to plasma ratio for MTG and 7HMG	5
Table S3. Statistical analyses of baseline values for hotplate response latency and locomotor	6
activity counts	
Table S4. Statistical analyses of effects of MTG and 7HMG on hotplate response latency and	7-11
locomotor activity counts	

Berthold et al., 7-hydroxymitragynine cannot explain mitragynine antinociception

Table S5. Tissue pharmacokinetic parameters of MTG in mice following a single oral dose of	12
165 mg/kg	12
Table S6. Tissue pharmacokinetic parameters of 7HMG in mice following a single oral dose	13
of 50 mg/kg	
Table S7. PK/PD model parameters for MTG and 7HMG	14-16
Figure S1. Tissue concentration time profiles of MTG after single oral dose of 165 mg/kg	17
Figure S2. Tissue concentration time profiles of 7HMG after single oral dose of 50 mg/kg	18
Figure S3. Goodness of fit plots for the PK/PD models of MTG and 7HMG	19-20

Table S1: Partial validation of UPLC/MS-MS method in different matrices. Measured concentrations are shown as mean \pm SD in ng/mL (N=6 per concentration). Precision and accuracy were measured over three different days and are shown as RSD and %Bias, respectively.

	MTG								
Concentration	Plasma			Brain			Kidney		
(ng/mL)	Measured	%	%	Measured	%	%	Measured	%	%
	Concentration	RSD	Bias	Concentration	RSD	Bias	Concentration	RSD	Bias
2	2.1 ± 0.3	14.9	2.5	3.1 ± 0.4	13.0	5.0	12.1 ± 0.2	9.5	5.0
5	4.9 ± 0.6	11.8	-1.5	6.3 ± 0.5	7.7	5.5	5.0 ± 0.4	7.9	-0.8
350	317.9 ± 11.4	3.6	-9.2	333.8 ± 14.2	4.2	-4.6	344.0 ± 20.6	6.0	-1.7
700	600.0 ± 27.5	4.6	-14.3	689.4 ± 34.8	5.0	-1.5	694.1 ± 13.7	2.0	-0.8
Concentration	Liv	ver		Lui	ng		Sple	een	
	Measured	%	%	Measured	%	%	Measured	%	%
(ng/mL)	Concentration	RSD	Bias	Concentration	RSD	Bias	Concentration	RSD	Bias
2	1.9 ± 0.4	19.6	-6.2	1.8 ± 0.3	17.2	-8.3	2.1 ± 0.3	15.4	5.1
5	4.9 ± 0.5	9.3	-3.0	4.3 ± 0.6	14.8	-13.6	4.6 ± 0.5	10.5	-8.2
350	386.1 ± 28.9	7.5	10.3	365.6 ± 31.0	8.5	4.5	349.6 ± 23.7	6.8	-0.9
700	738.4 ± 34.7	4.7	5.5	659.6 ± 92.3	14.0	-5.8	681.5 ± 57.5	7.6	-2.6
				7HM	G				
Concentration	Pla	sma		Bra	in		Kidı	ney	
(ng/mL)	Measured	%	%	Measured	%	%	Measured	%	%
	Concentration	RSD	Bias	Concentration	RSD	Bias	Concentration	RSD	Bias
2	2.0 ± 0.3	15.1	0.2	3.0 ± 0.4	13.8	-0.6	1.9 ± 0.0	1.0	-4.3
5	4.8 ± 0.2	4.5	-4.1	5.8 ± 0.7	12.3	-4.0	5.6 ± 0.8	14.5	12.4
350	323.6 ± 15.4	4.8	-7.5	336.1 ± 10.2	3.0	-4.0	372.1 ± 18.3	4.9	6.3
700	617.9 ± 27.1	4.4	-11.7	676.8 ± 27.7	4.1	-3.3	735.3 ± 15.5	2.1	5.0

Berthold et al., 7-hydroxymitragynine cannot explain mitragynine antinociception

Concentration	Liv	ver		Lui	ng		Sple	een	
(ng/mL)	Measured	%	%	Measured	%	%	Measured	%	%
(lig/lill2)	Concentration	RSD	Bias	Concentration	RSD	Bias	Concentration	RSD	Bias
2	1.8 ± 0.1	6.0	-10.4	1.8 ± 0.2	11.1	-10.0	2.1 ± 0.4	19.8	5.2
5	4.5 ± 0.4	7.8	-9.1	4.8 ± 0.2	4.5	-5.0	50.2 ± 0.2	4.0	-0.1
350	330.1 ± 10.4	3.2	-5.7	402.2 ± 39.3	9.8	14.9	365.7 ± 20.3	5.6	4.5
700	674.8 ± 15.8	2.3	-3.6	773.2 ± 44.7	5.8	10.5	740.4 ± 3.3	0.4	5.8

Berthold et al., 7-hydroxymitragynine cannot explain mitragynine antinociception

Table S2. Blood to plasma ratio for MTG and 7HMG. $K_{B/P}$ is the blood to plasma ratio (mean \pm SD, three replicates).

Ratios of close to one indicate that both MTG and 7HMG do not preferentially move into the red blood cells.

Compound	MTG	7HMG
K _{B/P} Females	1.0 ± 0.02	1.1 ± 0.04
K _{B/P} Males	0.9 ± 0.03	0.9 ± 0.03

Table S3. Statistical analyses of baseline values for hotplate response latency and locomotor activity counts as shown in Figures 2-5. The sample sizes are four mice per sex, per dose. Comparisons relative to vehicle group were made using a one-way ANOVA followed by *post hoc* Bonferroni *t* tests. No significant difference was found.

Factor	Hotplate Latency	Locomotor Activity Counts
Sex	F _{1,54} =0.863; P=0.357	F _{1,54} =3.63; P=0.062
Group	F _{8,54} =0.562; P=0.804	F _{8,54} =1.76; P=0.105
Group x Sex	F _{8,54} =1.68; P=0.124	F _{8,54} =0.381; P=0.926
Post-Hoc Test	Not applicable	Not applicable

Table S4. Statistical analyses of effects of MTG and 7HMG on hotplate response latency and locomotor activity counts as shown in Figures 2-5. The sample sizes are four mice per sex, per dose. Comparisons were made using a two-way ANOVA followed by *post hoc* Bonferroni *t* tests with results shown when effects were statistically significant. Significant differences are in bold.

MTG				
Factor	Hotplate Latency	Locomotor Activity Counts		
Sex	F _{1,192} =0.846; P=0.359	F _{1,216} =2.26; P=0.134		
Dose	F _{3,192} =594; P<0.001	F _{3,216} =20.0; P<0.001		
Time	F _{7,192} =4.40; P<0.001	F _{8,216} =56.8; P<0.001		
Sex x Dose	F _{3,192} =3.02; P=0.031	F _{3,216} =17.9; P<0.001		
Sex x Time	F _{7,192} =0.311; P=0.948	F _{8,216} =1.70; P=0.101		
Dose x Time	F _{21,192} =3.24; P<0.001	F _{24,216} =3.10; P<0.001		
Sex x Dose x Time	F _{21,192} =0.444; P=0.984	F _{24,216} =1.34; P=0.141		
Post-Hoc Test	Time (versus vehicle)	Time (versus vehicle)		
[Treatment (T:	T=30; 163 mg/kg (t=3.94; P<0.001) and 293 mg/kg	T=30; 293 mg/kg (t=5.31; P<0.001)		
Minute)]	(t=13.4; P<0.001)	T=60; 163 mg/kg (t=4.34; P<0.001)		
	T=60; 163 mg/kg (t=9.01; P<0.001) and 293 mg/kg	T=90; 163 mg/kg (t=2.63; P=0.027)		
	(t=12.2; P<0.001)			
	T=90; 163 mg/kg (t=11.3; P<0.001) and 293 mg/kg			
	(t=13.2; P<0.001)			
	T=120; 163 mg/kg (t=8.68; P<0.001) and 293 mg/kg			
	(t=13.3; P<0.001)			
	T=150; 163 mg/kg (t=9.35; P<0.001) and 293 mg/kg			
	(t=13.1; P<0.001)			
	T=180; 163 mg/kg (t=7.75; P<0.001) and 293 mg/kg			
	(t=12.8; P<0.001)			

Berthold et al., 7-hydroxymi	tragynine cannot explain mitragynine antinociception	
	T=210; 163 mg/kg (t=7.03; P<0.001) and 293 mg/kg	
	(t=12.8; P<0.001)	
	T=240; 163 mg/kg (t=4.79; P<0.001) and 293 mg/kg	
	(t=12.3; P<0.001)	
	7HMG	
Factor	Hotplate Latency	Locomotor Activity Counts
Sex	F _{1,192} =103; P<0.001	F _{1,216} =2.81; P=0.095
Dose	F _{3,192} =102; P<0.001	F _{3,216} =28.0; P<0.001
Time	F _{7,192} =19.7; P<0.001	F _{8,216} =8.36; P<0.001
Sex x Dose	F _{3,192} =37.7; P<0.001	F _{3,216} =0.867; P=0.459
Sex x Time	F _{7,192} =10.5; P<0.001	F _{8,216} =2.48; P=0.014
Dose x Time	F _{21,192} =5.86; P<0.001	F _{24,216} =3.36; P<0.001
Sex x Dose x Time	F _{21,192} =2.25; P=0.002	F _{24,216} =1.34; P=0.015
Post-Hoc Test	Time (versus vehicle)	Time (versus vehicle)
[Treatment (T:	T=30; 56 mg/kg (t=6.71; P<0.001) and 100 mg/kg	T=30; 100 mg/kg (t=3.38; P=0.003)
Minute)]	(t=12.6; P<0.001)	T=60; 100 mg/kg (t=5.98; P<0.001)
	T=210; 100 mg/kg (t=3.77; P<0.001)	T=90; 100 mg/kg (t=5.70; P<0.001)
	Time (versus vehicle in males)	T=120; 100 mg/kg (t=4.45; P<0.001)
	T=60; 32 mg/kg (t=4.20; P<0.001), 56 mg/kg (t=6.26;	T=150; 100 mg/kg (t=3.89; P<0.001)
	P<0.001) and 100 mg/kg (t=8.32; P<0.001)	
	T=90; 32 mg/kg (t=3.28; P=0.004), 56 mg/kg (t=6.08;	
	P<0.001) and 100 mg/kg (t=8.88; P<0.001)	
	T=120; 56 mg/kg (t=4.60; P<0.001) and 100 mg/kg	
	(t=7.99; P<0.001)	
	T=150; 56 mg/kg (t=4.84; P<0.001) and 100 mg/kg	
	(t=8.23; P<0.001)	
L	I	

Rerthold at al	/_hydrovymitragy	mine cannot evi	nlaın mıtram	unine anti	nocicer	ntion .
Berthold <i>et al.</i> , 7	/-II y GIOA y IIII Gag	mile camer cx	piam minag	ymme amu	HOCICCL	Juon

T=180;	56 mg/kg (t=2.54; P=0.036) and 100 mg/kg				
(t=4.30;	; P<0.001)				
<u>Sex</u>					
T=60; 3	32 mg/kg (t=4.53; P<0.001), 56 mg/kg (t=5.41				
P<0.00	1). and 100 mg/kg (t=6.29; P<0.001)				
T=90;	56 mg/kg (t=4.48; P<0.001) and 100 mg/kg				
(t=6.07;	; P<0.001)				
T=120;	56 mg/kg (t=4.45; P<0.001) and 100 mg/kg				
(t=7.62;	; P<0.001)				
T=150;	56 mg/kg (t=3.92; P<0.001) and 100 mg/kg				
(t=7.25;	; P<0.001)				
T=180;	100 mg/kg (t=4.01; P<0.001)				
1.0 mg/kg Naltrexone + MTG					

1.0 mg/kg Naltrexone + MTG

Factor	Hotplate Latency	Locomotor Activity Counts
Sex	F _{1,144} =12.7; P<0.001	F _{1,162} =4.28; P=0.040
Dose	F _{2,144} =2218; P<0.001	F _{2,162} =59.7; P<0.001
Time	F _{7,144} =1.18; P=0.317	F _{8,162} =199; P<0.001
Sex x Dose	F _{2,144} =8.58; P<0.001	F _{2,162} =2.03; P=0.134
Sex x Time	F _{7,144} =1.34; P=0.235	F _{8,162} =1.78; P=0.084
Dose x Time	F _{14,144} =0.394; P=0.975	F _{16,162} =10.8; P<0.001
Sex x Dose x Time	F _{14,144} =0.799; P=0.670	F _{16,162} =0.528; P=0.930
Post-Hoc Test	Not applicable (no significant interaction between Dose	Time (versus 293 mg/kg MG alone)
[Treatment (T:	and Time)	T=30; 1.0 mg/kg naltrexone + 293
Minute)]		mg/kg MG (t=12.0; P<0.001)
		T=60; 1.0 mg/kg naltrexone + 293
		mg/kg MG (t=6.36; P<0.001)

Berthold et al., 7-hydroxymi	tragynine cannot explain mitragynine antinociception	,
		T=90; 1.0 mg/kg naltrexone + 293
		mg/kg MG (t=5.01; P<0.001)
		T=120; 1.0 mg/kg naltrexone + 293
		mg/kg MG (t=3.54; P=0.002)
	1.0 mg/kg Naltrexone + 7HMG	
Factor	Hotplate Latency	Locomotor Activity Counts
Sex	F _{1,144} =31.5; P<0.001	F _{1,162} =0.963; P=0.328
Dose	F _{2,144} =206; P<0.001	F _{2,162} =67.7; P<0.001
Time	F _{7,144} =11.2; P<0.001	F _{8,162} =12.0; P<0.001
Sex x Dose	F _{2,144} =77.7; P<0.001	F _{2,162} =1.73; P=0.181
Sex x Time	F _{7,144} =3.95; P<0.001	F _{8,162} =2.15; P=0.034
Dose x Time	F _{14,144} =11.2; P<0.001	F _{16,162} =4.54; P<0.001
Sex x Dose x Time	F _{14,144} =4.41; P<0.001	F _{16,162} =1.60; P=0.074
Post-Hoc Test	Time (versus 293 mg/kg MG alone)	Time (versus 100 mg/kg MG alone)
[Treatment (T:	T=30; 1.0 mg/kg naltrexone + 100 mg/kg 7HMG (t=13.4;	T=30; 1.0 mg/kg naltrexone + 100
Minute)]	P<0.001)	mg/kg 7HMG (t=3.74; P<0.001)
	T=210; 1.0 mg/kg naltrexone + 100 mg/kg 7HMG (t=3.29;	T=60; 1.0 mg/kg naltrexone + 100
	P=0.003)	mg/kg 7HMG (t=7.00; P<0.001)
	Time (versus 293 mg/kg MG alone in males)	T=90; 1.0 mg/kg naltrexone + 100
	T=60; 1.0 mg/kg naltrexone + 100 mg/kg 7HMG (t=9.88;	mg/kg 7HMG (t=6.78; P<0.001)
	P<0.001)	T=120; 1.0 mg/kg naltrexone + 100
	T=90; 1.0 mg/kg naltrexone + 100 mg/kg 7HMG (t=8.75;	mg/kg 7HMG (t=5.18; P<0.001)
	P<0.001)	T=150; 1.0 mg/kg naltrexone + 100
	T=120; 1.0 mg/kg naltrexone + 100 mg/kg 7HMG (t=8.74;	mg/kg 7HMG (t=2.67; P=0.025)
	P<0.001)	

Berthold <i>et al.</i> , 7-hydroxymi	tragynine cannot explain mitragynine antinociception	
	T=150; 1.0 mg/kg naltrexone + 100 mg/kg 7HMG (t=8.60;	
	D 0.025)	
	P=0.025)	
	T=180; 1.0 mg/kg naltrexone + 100 mg/kg 7HMG (t=5.19;	
	D_0 025)	
	P=0.025)	

Table S5. Tissue pharmacokinetics parameters in male mice following a single oral dose of 165 mg/kg MTG. All values were corrected for residual blood and parameters determined using noncompartmental analysis. C_{max}: the maximum concentration, T_{max}: time to reach maximum concentration, AUC₀₋₄₈: area under the curve (exposure), MRT: mean residence time of a drug molecule in the body, AUC_{organ}/AUC_{plasma}: organ to plasma exposure ratio, AUC_{7HMG}/AUC_{MTG}: ratio of metabolite to parent.

MTG			7HMG as a metabolite of MTG					
Parameter								
	Liver	Kidney	Spleen	Lung	Liver	Kidney	Spleen	Lung
C _{max} (μg/mL or μg/g)	434.2	274.3	90.2	165.2	10.3	7.3	3.2	0.79
T _{max} (hr)	0.25	0.5	0.5	0.25	0.25	0.5	0.5	0.25
AUC ₀₋₄₈ (hr*μg/mL or hr*μg/g)	1506.9	900.7	268.5	838.0	37.0	17.5	9.8	2.1
MRT (hr)	5.6	4.8	5.2	4.8	5.3	3.4	4.2	5.5
AUC _{organ} AUC _{plasma}	28.6	17.1	5.1	15.9	26.4	12.5	7.0	1.5
AUC _{7HMG} AUC _{MTG}	-	-	-	-	0.02	0.02	0.04	0.003

Table S6. Tissue pharmacokinetics parameters in male mice following a single oral dose of 50 mg/kg 7HMG. All values were corrected for residual blood and parameters determined using noncompartmental analysis. C_{max} : the maximum concentration, T_{max} : time to reach maximum concentration, AUC_{0-8} : area under the curve (exposure), MRT: mean residence time of a drug molecule in the body, AUC_{organ}/AUC_{plasma} : organ to plasma exposure ratio.

	7HMG			
Parameter				
	Liver	Kidney	Spleen	Lung
C _{max} (μg/mL or μg/g)	54.3	48.6	23.6	13.8
T _{max} (hr)	0.25	0.5	0.5	0.5
AUC ₀₋₈ (hr*μg/mL or hr*μg/g)	82.6	76.8	28.7	19.1
MRT (hr)	1.6	1.6	1.5	2.0
$rac{AUC_{organ}}{AUC_{plasma}}$	5.4	5.1	1.9	1.3

Table S7. PK/PD model parameters for MTG and 7HMG. RSE is calculated as SEM/Value*100. k_a is the absorption rate constant, k_{e0} is the effect compartment rate constant, CL/F is the clearance, V_C/F (or V/F) is the volume of the central compartment, Q/F is the intercompartmental clearance, Vp/F is the volume of the peripheral compartment, γ represents the sigmoidicity of the compound, E0 is the baseline effect, E_{max} is the maximum pharmacodynamic effect, E_{c0} is the concentration at which 50% of the maximum pharmacodynamic effect is seen, β represents the difference between males and females, ω represents the interindividual variability of each parameter, and σ represents the overall error within the model.

	M	TG .	
Parameter	Value	SEM	RSE (%)
k _a (1/hr)	8.7	5.7	64.9
CL/F (L/hr)	0.1	0.0	13.6
$\beta_{\text{CL/F}}$ Sex	0.3	0.1	43.3
V _C /F (L/hr)	0.2	0.1	42.9
Q/F(L/hr)	7.6	-	-
V_p/F (L/hr)	0.3	0.1	24.1
γ	6.7	2.4	36.2
E0 (%)	2.9	1.3	45.5
E _{max} (%)	100.0	-	-
EC_{50} (µg/L)	3.8	0.5	13.7
Interindividual Variability	Value	SEM	RSE (%)
ω_{ka}	1.5	0.6	38.4
ω _{CL/F}	0.1	0.1	61.6
ω _{Vc/F}	0.4	0.2	54.9
ω _{Q/F}	3.1	1.0	33.6
$\omega_{Vp/F}$	0.2	-	-
ω_{γ}	0.4	0.5	107.0
ω_{E0}	4.5	1.3	29.3
ω_{Emax}	0.0	0.0	83.9
ω_{EC50}	0.2	0.1	58.4
Residual Error	Value	SEM	RSE (%)

SE		0.2		
Corrected Bayesian Information Criteria (BICc) Sampling Distribution		T-distribution with 5 degrees of freedom		
		2288.6		
Bayesian Information	Criteria (BIC)	2266.3		
Akaike Information	Criteria (AIC)	2233.0		
Objective Funct	ion Value	2192.98		
σ _a MPE	8.5	0.4	5.2	
σ _b Concentration	0.4	0.0	8.1	

7HMG				
Parameter	Value	SEM	RSE (%)	
k _a (1/hr)	93.63	6.45	6.89	
V/F (L)	0.15	0.0088	5.96	
β_{V} Sex	0.17	0.14	83.3	
CL/F (L/hr)	0.073	0.0054	7.32	
β_{CL} Sex	0.1	0.13	124	
k _{e0} (1/hr)	2.13	0.47	22.1	
β_{ke0}_Sex	0.76	0.4	52.4	
γ	8.46	2.77	32.8	
E0 (%)	2.03	1.14	56	
E _{max} (%)	100	-	-	
$EC_{50} \left(\mu g/L\right)$	3.19	0.34	10.7	
β_{EC50} Sex	0.53	0.17	32.8	
Interindividual Variability	Value	SEM	RSE (%)	
ω_{ka}	0.04	0.031	75.9	
$\omega_{V/F}$	0.081	-	-	
ω _{CL/F}	0.12	0.16	132	

Berthold et al., 7-hydroxymitragynine cannot	explain mitragynine antinociception	on		
$\omega_{\mathrm{ke}0}$	0.43	0.27	63.3	
ω_γ	1.18	0.3	25.5	
ω_{E0}	1.61	1.16	72.1	
ω_{Emax}	0.08	0.052	64.3	
ω _{EC50}	0.28	0.071	24.8	
Error Model Parameters	Value	SEM	RSE (%)	
σ _a Concentration	0.16	0.079	48.2	
σ_b Concentration	0.29	0.054	18.8	
$\sigma_{constant} \; MPE$	9.12	0.51	5.55	
Objective Functi	on Value	212	25.34	
Akaike Information (Criteria (AIC)	216	2169.34 2205.37 2226.49	
Bayesian Information	Criteria (BIC)	220		
Corrected Bayesian Informa	tion Criteria (BICc)	222		
Sampling Distr	ibution	T-distribution with	T-distribution with 5 degrees of freedom	
SE		0	.32	

Figure S1. Tissue concentration time profiles after single oral dose of 165 mg/kg MTG in male mice. All points represent the mean (N=4) and error bars represent the SD. *A*, MTG; *B*, 7HMG.




Figure S2. Tissue concentration time profiles after single oral dose of 50 mg/kg 7HMG in male mice. All points represent the mean (N=4) and error bars represent the SD.




Figure S3 Goodness of fit plots for the PK/PD model fitting of MTG and 7HMG. Plots include the observations versus predictions (top) with males as blue dots and females as pink/red dots. The distribution of the residuals (IWRES) versus the predictions are the middle plots of each panel (males = blue dots, females = pink/red dots). The visual predictive check with 5%, 50%, and 95% intervals displayed are in the bottom panel (males = SEX:0, females = SEX:1). *A*, MTG; *B*,

